Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?

Executive Summary

After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.


Related Content

Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival
Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce
Teva CEO Schultz Walks Smack Into A Rough Financial Situation
Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Nuvelution Puts Business Model Into Action With Teva/Austedo Deal
Teva Set For Immediate US Launch Of Austedo In Tardive Dyskinesia
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Lundbeck Restructures Around 5 Key Products; 1,000 Jobs To Go
Ex-Novo Nordisk protégé Schultz becomes Lundbeck CEO


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts